TYRA
Price:
$15.83
Market Cap:
$801.05M
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is...[Read more]
Industry
Biotechnology
IPO Date
2021-09-15
Stock Exchange
NASDAQ
Ticker
TYRA
According to Tyra Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -9.83. This represents a change of -15.61% compared to the average of -11.65 of the last 4 quarters.
The mean historical PE Ratio of Tyra Biosciences, Inc. over the last ten years is -85.66. The current -9.83 PE Ratio has changed 1.05% with respect to the historical average. Over the past ten years (40 quarters), TYRA's PE Ratio was at its highest in in the December 2022 quarter at 4.11. The PE Ratio was at its lowest in in the September 2020 quarter at -62.47.
Average
-85.66
Median
-22.31
Minimum
-272.53
Maximum
-6.15
Discovering the peaks and valleys of Tyra Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 39.01%
Maximum Annual PE Ratio = -6.15
Minimum Annual Increase = -81.21%
Minimum Annual PE Ratio = -272.53
Year | PE Ratio | Change |
---|---|---|
2023 | -8.56 | 39.01% |
2022 | -6.15 | -72.41% |
2021 | -22.31 | -81.21% |
2020 | -118.74 | -56.43% |
The current PE Ratio of Tyra Biosciences, Inc. (TYRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-12.34
5-year avg
-85.66
10-year avg
-85.66
Tyra Biosciences, Inc.’s PE Ratio is less than Connect Biopharma Holdings Limited (7.24), less than RAPT Therapeutics, Inc. (-0.39), less than Xilio Therapeutics, Inc. (-0.90), less than Mineralys Therapeutics, Inc. (-4.06), greater than Gracell Biotechnologies Inc. (-29.05), less than Theseus Pharmaceuticals, Inc. (-6.29), less than Monte Rosa Therapeutics, Inc. (-5.83), less than Design Therapeutics, Inc. (-6.66), less than Erasca, Inc. (-4.79), less than Werewolf Therapeutics, Inc. (-1.34), less than Ikena Oncology, Inc. (-1.38), less than Stoke Therapeutics, Inc. (-6.11), less than PMV Pharmaceuticals, Inc. (-1.61), less than Pharvaris N.V. (-8.69), less than Molecular Partners AG (-2.50), less than Century Therapeutics, Inc. (-0.79), greater than Edgewise Therapeutics, Inc. (-24.30), less than C4 Therapeutics, Inc. (-2.80), less than Cullinan Oncology, Inc. (-5.10),
Company | PE Ratio | Market cap |
---|---|---|
7.24 | $55.25M | |
-0.39 | $37.75M | |
-0.90 | $39.21M | |
-4.06 | $621.09M | |
-29.05 | $989.87M | |
-6.29 | $181.50M | |
-5.83 | $521.60M | |
-6.66 | $318.21M | |
-4.79 | $763.36M | |
-1.34 | $84.67M | |
-1.38 | $82.52M | |
-6.11 | $605.41M | |
-1.61 | $83.31M | |
-8.69 | $1.20B | |
-2.50 | $216.81M | |
-0.79 | $102.89M | |
-24.30 | $3.05B | |
-2.80 | $300.00M | |
-5.10 | $730.17M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tyra Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tyra Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Tyra Biosciences, Inc.'s PE Ratio?
How is the PE Ratio calculated for Tyra Biosciences, Inc. (TYRA)?
What is the highest PE Ratio for Tyra Biosciences, Inc. (TYRA)?
What is the 3-year average PE Ratio for Tyra Biosciences, Inc. (TYRA)?
What is the 5-year average PE Ratio for Tyra Biosciences, Inc. (TYRA)?
How does the current PE Ratio for Tyra Biosciences, Inc. (TYRA) compare to its historical average?